AMEA
IHC testing is available for add-on ordering.
Talk to a Guardant Health representative to learn more.
Analyzes DNA and RNA, and includes epigenomic-based features.1*
MSI, microsatellite instability; PD-L1, programmed death-ligand 1;
TMB, tumor mutation burden.
*Guardant360 Liquid analyzes 742 DNA genes and fusions in 367 RNA genes, plus TMB, MSI status, and methylation-based features. RNA is automatically included, but providers can opt out via the Test Requisition Form.
Important note: Guardant360 Tissue was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.